Preterm Birth Clinical Trial
— NIEM-OOfficial title:
Non-invasive Electrophysiological Monitoring in High Risk Pregnancies at the Obstetric High Care: the NIEM-O Study
The goal of this single centre cohort intervention study with historical controls, is to investigate the effect of implementing continuous antepartum electrophysiological CTG (eCTG) monitoring at the Obstetric High Care (OHC), on perinatal and maternal outcomes and obstetric care. The main aim is to investigate the effect of both monitoring methods on: - primary outcome: perinatal outcomes (a composite of perinatal mortality or major neonatal morbidity) until hospital discharge - secondary outcomes: Maternal mortality, neonatal morbidity, satisfaction for both patient and caregiver, duration of pregnancy, switch of monitoring method, duration of admission to the OHC, timing (planned or emergency) and number of obstetric interventions (such as caesarean section), and admission and duration of admission to the NICU (neonatal intensive care unit). Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
Status | Recruiting |
Enrollment | 1911 |
Est. completion date | November 20, 2025 |
Est. primary completion date | November 20, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - =18 years old - Singleton pregnancy =23+0 weeks of gestation - Requiring hospitalization to the OHC for maternal or fetal surveillance (i.e. imminent preterm delivery(PPI), PE, HELLP, pregnancy induced hypertension (PIH), FGR, fetal distress, vaginal blood loss, fetal congenital anomalies) - Parents wishing for fetal monitoring Exclusion Criteria: - Multiple pregnancy - Insufficient knowledge of Dutch or English language - Contraindications to abdominal patch placement (dermatologic diseases of the abdomen precluding preparation of the abdomen with abrasive paper) - Women connected to an external or implanted electrical stimulator (e.g. a pacemaker - exclusion due to possible signal interference) - Fetal and/or maternal cardiac disease (i.e. arrhythmia, congenital defect) - Treatment plan (with intervention planned within 24 hours after admission) already made before inclusion is completed - Women admitted with a clinical diagnosis of sepsis with hypotension (i.e. septic shock). |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maxima Medical Centre | Veldhoven | Noord-Brabant |
Lead Sponsor | Collaborator |
---|---|
Maxima Medical Center | ZonMw: The Netherlands Organisation for Health Research and Development |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of perinatal mortality and major neonatal morbidity | A composite outcome consisting of: 1. Incidence of perinatal mortality and/or 2.Incidence of a major neonatal morbidity (defined as either: Intraventricular hemorrhage (IVH) grade three or more, Periventricular leukomalacia (PVL) grade two or more, Moderate or severe bronchopulmonary dysplasia (BPD), Necrotizing enterocolitis (NEC) grade two or more, or Retinopathy of prematurity (ROP) necessitating laser therapy). | during admission (immediately after birth until hospital discharge) or until at least 4 weeks after birth | |
Secondary | Incidence of maternal mortality | Incidence of maternal mortality in percentages | From moment of inclusion until six weeks after giving birth | |
Secondary | Incidence of neonatal morbidity | Incidence of other neonatal morbidity then described in the primary outcome (i.e. IVH grade 1-2, PVL grade 1, mild BPD, NEC grade 1, ROP not necessitating laser therapy, hypoxic ischemic encephalopathy, neonatal seizures, neonatal sepsis (culture proven), need for intubation on the delivery room, mechanical ventilation within the first 72 hours after birth, antibiotics within the first 72 hours after birth, spontaneous intestinal perforation (SIP) necessitating surgery, surfactant treatment, Apgar score <7 after 5 minutes, severe metabolic acidosis (pH <7.05 and base deficit =12mmol/L). | From inclusion assessed up to 6 months after inclusion | |
Secondary | Assesment using a surveys (D-QUEST) to measure patient satisfaction | Patient satisfaction of the given monitoring method, measured using a surveys: D-QUEST (comprises twelve items with a 5-point rating system. A high level of satisfaction is correlated with a high D-QUEST score, (Score between 14 and 70). The questionnaire is given ones to the patient during the trial. | At discharge, assessed up to 1 month. | |
Secondary | Assesment using a survey (EQ5D5L) to measure patient satisfaction | Patient satisfaction of the given monitoring method, measured using a survey: EQ5D5L (This assessment tool assigns a numerical value to each response level (i.e., 1 for "no problems", 5 for "extreme problems"/"unable to") and the summing of these values across the five items, results in a score. The score is then placed on a scale, which is numbered from 0 to 100. 100 means the best health one can imagine. 0 means the worst health one can imagine). The questionnaire is given ones to the patient during the trial. | EQ5D5L questionnaire is given on day 1 of the admission (day 1 after inclusion). and assessed up to 1 month. | |
Secondary | Assesment using one survey (Browns survey) to measure caregiver satisfaction | Caregiver satisfaction is measured using Browns survey: purpose of this survey is to assess obstetricians' and midwives' use of current fetal-monitoring techniques and their views towards continuous monitoring, using multiple choice options (ranging from strongly agree to strongly disagree). | Caregivers are invited to fill in the questionnaire at baseline and at 1 year | |
Secondary | Duration of pregnancy in days | Duration of pregnancy measured in days | Measured from first day of pregnancy until birth, pregnancy period must be related to pregnancy at time of inclusion in the study. Assessed up to 5,5 months after inclusion. | |
Secondary | Switch of monitoring method from eCTG to CTG monitoring | Percentage of participants in which a switch is made from eCTG to CTG monitoring | From inclusion assessed up to 6 months after inclusion | |
Secondary | Duration of admission to the Obstetric High Care in days | Duration of admission to the Obstetric High Care measured in days | From inclusion assessed up to 6 months after inclusion | |
Secondary | Timing of obstetric interventions (caesarean section) | Planned or emergency caesarean section | From inclusion assessed up to 6 months after inclusion | |
Secondary | Number of obstetric interventions (caesarean section) | Number of obstetric intervention is measured as number of caesarean sections | From inclusion assessed up to 6 months after inclusion | |
Secondary | Admission (yes/no) to the NICU (neonatal intensive care unit) | Admission to NICU is qualified as yes or no | From inclusion assessed up to 6 months after inclusion | |
Secondary | Duration of admission to the NICU (neonatal intensive care unit) in days. | Duration of admission to the NICU (neonatal intensive care unit) is measured in days. | From inclusion assessed up to 6 months after inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Completed |
NCT05502510 -
Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
|
||
Not yet recruiting |
NCT03418311 -
Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome
|
N/A | |
Not yet recruiting |
NCT03418012 -
Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB
|
N/A | |
Completed |
NCT02993744 -
Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone
|
N/A | |
Active, not recruiting |
NCT02673216 -
Infection and Adverse Pregnancy Outcome
|
||
Completed |
NCT01683565 -
Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood
|
Phase 4 | |
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Completed |
NCT01412931 -
Protein and Ultrasound Indicators of Preterm Birth
|
N/A | |
Completed |
NCT02606058 -
The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?
|
N/A | |
Terminated |
NCT03715530 -
Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women
|
N/A | |
Completed |
NCT00422526 -
Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial
|
Phase 3 | |
Enrolling by invitation |
NCT04251260 -
Effectiveness of Positioning in Preterm Neonates
|
N/A | |
Completed |
NCT03668860 -
India Dexamethasone and Betamethasone
|
Phase 1 | |
Recruiting |
NCT03638037 -
Correlation Between Maternal Vitamin D Level And Preterm Birth
|
||
Completed |
NCT02225353 -
Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
|
Phase 2 | |
Recruiting |
NCT03992534 -
The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth
|
Phase 1 | |
Completed |
NCT03144141 -
Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery
|
N/A | |
Completed |
NCT05210985 -
Examination of the Relationship Between Home Affordances With Development
|
||
Completed |
NCT04811742 -
Effect of Immersion Bathing and Showering Applications on Comfort Level and Physiological Parameters of Newborn
|
N/A |